Individual Patient Compassionate Use of Fedratinib
Compassionate Use of Fedratinib for Patients Who Have Previously Received TG101348, SAR302503 or Fedratinib
1 other identifier
expanded_access
N/A
1 country
1
Brief Summary
This is an expanded access program (EAP) for eligible participants designed to provide access to fedratinib. Expanded access is only available in markets where fedratinib is not yet approved.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
October 25, 2018
CompletedFirst Posted
Study publicly available on registry
October 29, 2018
CompletedSeptember 18, 2020
September 1, 2020
October 25, 2018
September 17, 2020
Conditions
Keywords
Interventions
Oral fedratinib administered as directed by treating physician.
Eligibility Criteria
You may qualify if:
- Subjects will be considered if they received TG101348, SAR302503 or Fedratinib as a participant on a clinical trial prior to 31 Jan 2018.
You may not qualify if:
- Subject is eligible for enrollment in an ongoing clinical trial using Fedratinib or has been treated with Fedratinib after 31 Jan 2018.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Celgene
Summit, New Jersey, 07901, United States
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Central Study Contacts
Study Design
- Study Type
- expanded access
- Sponsor Type
- INDUSTRY
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
October 25, 2018
First Posted
October 29, 2018
Last Updated
September 18, 2020
Record last verified: 2020-09